Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01680965 · ClinicalTrials.gov registry record · Phase 1
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
A Phase 1 study of Chronic Graft Versus Host Disease, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 4
- Study locations
NCT01680965 is a Phase 1 study of Chronic Graft Versus Host Disease that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 44 participants, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (62% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01680965, a Phase 1 study of Chronic Graft Versus Host Disease, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 4
- Study locations
Study Summary
To study the safety and side effects of Ofatumumab in the treatment of chronic graft-versus-host disease (GvHD). This study will also evaluate effectiveness of Ofatumumab when added to standard steroid treatment for chronic graft-versus-host disease
Conditions Studied
Interventions
- DRUG Ofatumumab
Study Locations (4)
Arizona
- Mayo Clinic Cancer Center - Phoenix
Florida
- H.Lee Moffitt Cancer Center & Research Institute - Tampa
Minnesota
- University of Minnesota - Minneapolis
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-11-14 |
| Est. Completion | 2020-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01680965
The ClinicalTrials.gov registry entry for NCT01680965 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (62% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Ofatumumab is the first listed.
NCT01680965 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01680965 about?
NCT01680965 is a clinical study titled "Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease". To study the safety and side effects of Ofatumumab in the treatment of chronic graft-versus-host disease (GvHD). This study will also evaluate effectiveness of Ofatumumab when added to standard steroid treatment for chronic graft-versus-host disease
What is the current status of trial NCT01680965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2012-11-14. Estimated completion is 2020-08-30.
What conditions does trial NCT01680965 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.
What interventions are being tested in trial NCT01680965?
The interventions under investigation include: Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01680965?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01680965 being conducted?
This trial has 4 study locations across Arizona, Florida, Minnesota, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
RECRUITING · Phase 1
-
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
ACTIVE NOT RECRUITING · Phase 1
-
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
ACTIVE NOT RECRUITING · Phase 1
-
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 1
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.